Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 83-94

  Yu, Shan ^a   Jia, Lin ^b   Zhang, Yan ^b   Wu, Dinglan ^b   Xu, Zhenyu ^b   Ng, Chi Fai ^b   To, Kenneth K W ^b   Huang, Yu ^b   Chan, Franky L ^b  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

Androgen receptor; Antiandrogen resistance; Bicalutamide; Endothelial nitric oxide synthase; Nitric oxide; Prostate cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; BICALUTAMIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSACTIVATION;

ANDROGEN ANTAGONISTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NITRIC OXIDE SYNTHASE TYPE III; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84868507799     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.006     Document Type: Article

References (60)

1. Culig Z., Bartsch G., Hobisch A. Antiandrogens in prostate cancer endocrine therapy. Curr. Cancer Drug Targets 2004, 4:455-461.
2. Wirth M.P., Hakenberg O.W., Froehner M. Antiandrogens in the treatment of prostate cancer. Eur. Urol. 2007, 51:306-314.
3. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
4. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12:1665-1671.
5. Bonkhoff H., Berges R. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010, 70:100-112.
6. Lee Y.F., Lin W.J., Huang J., Messing E.M., Chan F.L., Wilding G., Chang C. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 2002, 62:6039-6044.
7. Grzywacz M.J., Yang J.M., Hait W.N. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 2003, 63:2492-2498.
8. Edwards J., Bartlett J.M. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int. 2005, 95:1327-1335.
9. Hara T., Kouno J., Nakamura K., Kusaka M., Yamaoka M. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate 2005, 65:268-275.
10. Zhang M., Latham D.E., Delaney M.A., Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005, 24:2474-2482.
11. Vias M., Burtt G., Culig Z., Veerakumarasivam A., Neal D.E., Mills I.G. A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate 2007, 67:190-202.
12. Colabufo N.A., Pagliarulo V., Berardi F., Contino M., Inglese C., Niso M., Ancona P., Albo G., Pagliarulo A., Perrone R. Bicalutamide failure in prostate cancer treatment: involvement of multi drug resistance proteins. Eur. J. Pharmacol. 2008, 601:38-42.
13. Feng S., Tang Q., Sun M., Chun J.Y., Evans C.P., Gao A.C. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol. Cancer Ther. 2009, 8:665-671.
14. Gravina G.L., Biordi L., Martella F., Flati V., Ricevuto E., Ficorella C., Tombolini V., Festuccia C. Epigenetic modulation of PTEN expression during antiandrogen therapies in human prostate cancer. Int. J. Oncol. 2009, 35:1133-1139.
15. Katayama H., Murashima T., Saeki Y., Nishizawa Y. The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines. Int. J. Oncol. 2010, 36:553-562.
16. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumor progression. Nat. Rev. Cancer 2006, 6:521-534.
17. Ridnour L.A., Thomas D.D., Donzelli S., Espey M.G., Roberts D.D., Wink D.A., Isenberg J.S. The biphasic nature of nitric oxide responses in tumor biology. Antioxid. Redox Signal. 2006, 8:1329-1337.
18. Klotz T., Bloch W., Volberg C., Engelmann U., Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998, 82:1897-1903.
19. Aaltomaa S.H., Lipponen P.K., Viitanen J., Kankkunen J.P., Ala-Opas M.Y., Kosma V.M. The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int. 2000, 86:234-239.
20. Aaltomaa S.H., Lipponen P.K., Kosma V.M. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res. 2001, 21:3101-3106.
21. Baltaci S., Orhan D., Gögüs C., Türkölmez K., Tulunay O., Gögüs O. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int. 2001, 88:100-103.
22. Uotila P., Valve E., Martikainen P., Nevalainen M., Nurmi M., Härkönen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res. 2001, 29:23-28.
23. Wang J., Torbenson M., Wang Q., Ro J.Y., Becich M. Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol. Oncol. 2003, 21:117-122.
24. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., Battistini L., Iafrate M., Prayer-Galetti T., Pagano F., Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 2005, 201:1257-1268.
25. Cronauer M.V., Ince Y., Engers R., Rinnab L., Weidemann W., Suschek C.V., Burchardt M., Kleinert H., Wiedenmann J., Sies H., Ackermann R., Krönke K.D. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer. Oncogene 2007, 26:1875-1884.
26. Nanni S., Benvenuti V., Grasselli A., Priolo C., Aiello A., Mattiussi S., Colussi C., Lirangi V., Illi B., D'Eletto M., Cianciulli A.M., Gallucci M., De Carli P., Sentinelli S., Mottolese M., Carlini P., Strigari L., Finn S., Mueller E., Arcangeli G., Gaetano C., Capogrossi M.C., Donnorso R.P., Bacchetti S., Sacchi A., Pontecorvi A., Loda M., Farsetti A. Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J. Clin. Invest. 2009, 119:1093-1108.
27. Sanli O., Kucukgergin C., Gokpinar M., Tefik T., Nane I., Seckin S. Despite the lack of association between different genotypes and the presence of prostate cancer, endothelial nitric oxide synthase a/b (eNOS4a/b) polymorphism may be associated with advanced clinical stage and bone metastasis. Urol. Oncol. 2011, 29:183-188.
28. Medeiros R., Morais A., Vasconcelos A., Costa S., Pinto D., Oliveira J., Lopes C. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur. J. Cancer Prev. 2002, 11:343-350.
29. Marangoni K., Araújo T.G., Neves A.F., Goulart L.R. The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression. BMC Cancer 2008, 8:273.
30. Lee K.M., Kang D., Park S.K., Berndt S.I., Reding D., Chatterjee N., Chanock S., Huang W.Y., Hayes R.B. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 2009, 30:621-625.
31. Cheung C.P., Yu S., Wong K.B., Chan L.W., Lai F.M., Wang X., Suetsugi M., Chen S., Chan F.L. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J. Clin. Endocrinol. Metab. 2005, 90:1830-1844.
32. Yu S., Wang X., Ng C.F., Chen S., Chan F.L. ERRγ suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res. 2007, 67:4904-4914.
33. WAF/CIP1 induction and as a potential therapeutic target in prostate cancer. Oncogene 2008, 27:3313-3328.
34. Yu S., Wong S.L., Lau C.W., Huang Y., Yu C.M. Oxidized LDL at low concentration promotes in-vitro angiogenesis and activates nitric oxide synthase through PI3K/Akt/eNOS pathway in human coronary artery endothelial cells. Biochem. Biophys. Res. Commun. 2011, 407:44-48.
35. Teyssier C., Bianco S., Lanvin O., Vanacker J.M. The orphan receptor ERRα interferes with steroid signaling. Nucleic Acids Res. 2008, 36:5350-5361.
36. Hara T., Miyazaki J., Araki H., Yamaoka M., Kanzaki N., Kusaka M., Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003, 63:149-153.
37. Hobisch A., Fritzer A., Comuzzi B., Fiechtl M., Malinowska K., Steiner H., Bartsch G., Culig Z. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate 2006, 66:413-420.
38. Ishikura N., Kawata H., Nishimoto A., Nakamura R., Ishii N., Aoki Y. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate 2010, 70:457-466.
39. Kawata H., Ishikura N., Watanabe M., Nishimoto A., Tsunenari T., Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010, 70:745-754.
40. Kawabata R., Oie S., Oka T., Takahashi M., Kanayama H., Itoh K. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant prostate cancer cells. Int. J. Oncol. 2011, 38:665-676.
41. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
42. Galigniana M.D., Piwien-Pilipuk G., Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide. Mol. Pharmacol. 1999, 55:317-323.
43. Garbán H.J., Márquez-Garbán D.C., Pietras R.J., Ignarro L.J. Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc. Natl. Acad. Sci. USA 2005, 102:2632-2636.
44. Chlenski A., Nakashiro K., Ketels K.V., Korovaitseva G.I., Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001, 47:66-75.
45. Tepper C.G., Boucher D.L., Ryan P.E., Ma A.H., Xia L., Lee L.F., Pretlow T.G., Kung H.J. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 2002, 62:6606-6614.
46. Linja M.J., Savinainen K.J., Saramäki O.R., Tammela T.L., Vessella R.L., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
47. Edwards J., Krishna N.S., Grigor K.M., Bartlett J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 2003, 89:552-556.
48. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., Reuter V., Gerald W.L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 2004, 164:217-227.
49. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyer C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
50. Brown R.S., Edwards J., Dogan A., Payne H., Harland S.J., Bartlett J.M., Masters J.R. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J. Pathol. 2002, 198:237-244.
51. xL expression. Oncogene 2004, 23:4993-5003.
52. Muzandu K., Shaban Z., Ishizuka M., Kazusaka A., Fujita S. Nitric oxide enhances catechol estrogen-induced oxidative stress in LNCaP cells. Free Radic. Res. 2005, 39:389-398.
53. Wang D., Lu S., Dong Z. Regulation of TGF-β1 gene transcription in human prostate cancer cells by nitric oxide. Prostate 2007, 67:1825-1833.
54. Ng Q.S., Goh V., Milner J., Stratford M.R., Folkes L.K., Tozer G.M., Saunders M.I., Hoskin P.J. Effect of nitric-oxide synthesis on tumor blood volume and vascular activity: a phase I study. Lancet Oncol. 2007, 8:111-118.
55. Siemens D.R., Heaton J.P., Adams M.A., Kawakami J., Graham C.H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009, 74:878-883.
56. Stewart G.D., Nanda J., Brown D.J., Riddick A.C., Ross J.A., Habib F.K. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signaling pathway. Int. J. Cancer 2009, 124:223-232.
57. Polytarchou C., Hatziapostolou M., Poimenidi E., Mikelis C., Papadopoulou A., Parthymou A., Papadimitriou E. Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase β/ζ. Int. J. Cancer 2009, 124:1785-1793.
58. Baritaki S., Huerta-Yepez S., Sahakyan A., Karagiannides I., Bakirtzi K., Jazirehi A., Bonavida B. Mechanism of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle 2010, 9:4931-4940.
59. Donia M., Maksimovic-Ivanic D., Mijatovic S., Mojic M., Miljkovic D., Timotijevic G., Fagone P., Caponnetto S., Al-Abed Y., McCubrey J., Stosic-Grujicic S., Nicoletti F. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 2011, 10:492-499.
60. Thomas L.N., Morehouse T.J., Too C.K. Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells. Prostate 2012, 72:450-460.